Japanese Semiconductors Stock News

Wondering whether NEC is offering fair value at its current share price of ¥4,046, or if the market is missing something that you can see. The stock has seen mixed recent returns, with a 1.4% gain over the last 7 days, a 3.5% decline over 30 days, a 25.5% decline year to date, and a 36.8% return over the past year, alongside a very large 3 year return and a 228.8% return over 5 years. These moves have come as investors continue to digest broader newsflow around NEC's role in software and...

Recent Share Performance And Business Scale Mitsui (TSE:8031) has attracted attention after a recent 2.7% daily gain, which capped a month where the stock returned about 14.7%. Over the past 3 months, the stock showed a 37.4% total return. Over the past year, Mitsui’s total return of about 146% and year to date return of 34.3% sit alongside annual revenue of ¥14.0b and net income of ¥860.1m. Together, these figures highlight the company’s current scale. See our latest analysis for Mitsui. The...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Uniform Next Co., Ltd.'s ( TSE:3566 ) robust earnings report didn't manage to move the market for its stock. We did...

Lion Corporation ( TSE:4912 ) announced strong profits, but the stock was stagnant. Our analysis suggests that...

In March 2026, NGK Insulators, Ltd. raised its year-end dividend forecast for the fiscal year ending March 31, 2026 to ¥42 per share, lifting the expected annual dividend to ¥80 per share, citing steady performance in its Environment and Digital Society businesses. This dividend revision underlines management’s emphasis on shareholder returns, including a medium-term goal of a 3% dividend on equity ratio and a consolidated payout ratio around 30%. Next, we’ll examine how NGK’s higher...

Why Asahi Kasei (TSE:3407) is on investor radars today Asahi Kasei (TSE:3407) has attracted attention after recent share price moves, with the stock last closing at ¥1,560 and showing mixed returns over the past month and past 3 months. See our latest analysis for Asahi Kasei. Recent moves fit into a broader picture where the 90 day share price return of 12.31% and year to date gain of 9.86% contrast with a 1 year total shareholder return of 64.23%, suggesting earlier momentum is cooling. If...

Mitsubishi Motors North America reported that first-quarter 2026 sales fell 15% year over year to 26,884 units, largely due to the sell-through of the Mirage subcompact, while its SUV lineup achieved more than 10% growth in the same period. Later in 2026, the company plans to launch its first battery-electric vehicle and an off-road-focused Outlander variant, signaling a shift toward higher-value models and electrification within its Momentum 2030 plan. We’ll now examine how Mitsubishi’s...

Nissan Motor (TSE:7201) is back in focus after executives highlighted plans to expand US manufacturing, localize e Power production in Tennessee, and introduce a hybrid model to the American market. See our latest analysis for Nissan Motor. These US manufacturing plans arrive as the ¥355.3 share price sits below its year to date level, with recent 1 day and 7 day share price returns turning positive but longer term total shareholder returns remaining weak. If Nissan's US push has you thinking...

DeNA has now completed its previously announced share repurchase program, buying back 4,133,700 shares, or 3.71% of its stock, between February 26 and March 31, 2026, for a total outlay of ¥10,688.79 million. This sizable buyback removes a meaningful portion of shares from the market, which can enhance per-share metrics and underline management’s confidence in the business. Next, we’ll examine how completing this ¥10,688.79 million share repurchase could reshape DeNA’s investment narrative...

Toda’s completed buyback and share cancellation Toda (TSE:1860) has completed a share buyback and cancellation of over 4.65 million shares, reducing its outstanding share count and refining its capital structure following a recent board meeting approval. See our latest analysis for Toda. At a share price of ¥1,479.0, Toda’s recent 1 day share price return of 0.58% and 90 day share price return of 16.82% sit alongside a 1 year total shareholder return of 82.83%. This suggests recent buyback...

Mesirow Alternative Credit has entered a new partnership with GMO Payment Gateway (TSE:3769) and GMO-Z.com PAYMENT GATEWAY USA, with GMO committing investment capital to specialty finance transactions sourced by Mesirow. See our latest analysis for GMO Payment Gateway. Investors appear to be reacting positively to the Mesirow partnership, with a 1 month share price return of 14.03% and a 7 day share price return of 4.54% lifting the stock to ¥8,542, even as the 3 year total shareholder return...

NOF has completed its previously announced share repurchase, buying back 1,680,600 shares, or 0.74% of its stock, for ¥4,999.84 million between February 13 and March 23, 2026. This completed buyback reduces the share count and may be interpreted by investors as a sign of management confidence in the company’s outlook. We will now examine how the completion of this buyback program shapes NOF’s investment narrative over the near term. Find 21 companies with promising cash flow potential yet...

Unicharm has completed its previously announced share buyback program, repurchasing 18,826,800 shares, or 1.08% of its outstanding stock, for ¥18,450.84 million between February 12 and March 31, 2026. This concentrated repurchase effort highlights management’s focus on returning excess capital and refining the company’s equity base to support long-term shareholder value priorities. We’ll now examine how the completion of this sizeable share repurchase shapes Unicharm’s investment narrative,...

Why Suzuki Motor (TSE:7269) Is On Investors’ Radar Today Suzuki Motor (TSE:7269) has drawn attention after a period of mixed share performance, with the stock showing negative returns over the past week, month and past 3 months, yet a positive total return over the past year. See our latest analysis for Suzuki Motor. At a share price of ¥1,838.5, Suzuki Motor’s recent 1 day, 7 day and 30 day share price returns show pressure building on the downside, even as the 1 year, 3 year and 5 year...

In March 2026, Rohto Pharmaceutical Co., Ltd. (TSE:4527) announced a share repurchase program of up to 1,500,000 shares, or 0.66% of its share capital, for ¥3,000,000,000, running through December 31, 2026. The move, approved by the Board of Directors, is aimed at improving capital efficiency and giving the company more flexibility in how it manages its equity base. Next, we will examine how this newly authorized share repurchase program could shape Rohto Pharmaceutical's investment...

Why Japan Petroleum Exploration’s new bond shelf matters for investors Japan Petroleum Exploration (TSE:1662) has filed a shelf registration in Japan for up to ¥60 billion in bonds. This puts a potential funding option on the table that could influence its future capital mix. See our latest analysis for Japan Petroleum Exploration. The share price has climbed to ¥2,574, with a 30 day share price return of 8% and a 90 day share price return of 64%. The 1 year total shareholder return is around...

Why Aisin’s Recent Share Performance Has Caught Investor Attention Aisin (TSE:7259) has drawn interest after a mixed stretch in its share performance, with a roughly 8% decline over the past month and a 23% decline in the past 3 months. This short term weakness sits alongside a year to date decline of about 25%, even as the stock shows a total return of around 58% over the past year and very large gains over 3 and 5 years. See our latest analysis for Aisin. At a share price of ¥2,245.5,...

Advantest (TSE:6857) has announced euro-denominated convertible bonds due 2031, targeting a total issue size of ¥100b. The company plans to use the proceeds to expand semiconductor test equipment production, secure key inventory, and accelerate development of next generation solutions. The bonds come with a 60% conversion premium, with management highlighting an aim to limit shareholder dilution while raising growth capital. Advantest’s new funding plan follows a 1-year share price gain of...

JX Advanced Metals (TSE:5016) is taking part in a private placement for Fireweed Metals, securing an equity position in the company. The funding supports Fireweed Metals' mining projects in Canada focused on critical minerals. The transaction includes participation alongside other industry players involved in multiple large mining developments. For JX Advanced Metals, known for its materials and metals operations, this move extends its reach into Canadian critical mineral projects at a time...

KDDI Corporation recently reported earnings for the nine months ended December 31, 2025, with sales rising to ¥4,471,796 million and net income reaching ¥545,541 million, alongside board discussions on director nominations. The increase in basic earnings per share from ¥127.46 to ¥141.10 highlights how profit growth outpaced sales expansion over the period. Next, we’ll examine how this earnings improvement, particularly the jump in earnings per share, may influence KDDI’s existing...

As global markets navigate the complexities of Middle East tensions and energy market volatility, major U.S. stock indexes have ended a turbulent week higher, with smaller-cap indexes also showing solid gains. In this environment, high-growth tech stocks continue to capture investor attention as they offer potential for significant returns amidst geopolitical and economic shifts.

In a global market environment characterized by geopolitical tensions and energy market volatility, investors are seeing major U.S. stock indexes rally amid signs of potential de-escalation in the Middle East. As markets navigate these uncertainties, identifying stocks trading below their intrinsic value can provide opportunities for those looking to capitalize on potential undervaluation in sectors resilient to current economic shifts.

In March 2026, Chugai Pharmaceutical reported that partner Roche would discontinue clinical development of GYM329 (emugrobart) for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after Phase II/III data showed insufficient functional benefit despite good safety and target engagement. An important nuance for investors is that while these neuromuscular programs are ending, Roche and Chugai are continuing Phase II development of emugrobart in obesity, where the biological and...